Abha A. Gupta

Hospital for Sick Children
Country flagCanada

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (12)

Year:

2026

Year:

2026

A cancer diagnosis disrupts the social networks of adolescents and young adults (AYAs), impacting their overall health and wellbeing. This cross-sectional study examined the social network integration (SNI; size and frequency of contact) of AYAs with cancer in Canada. A survey was distributed to AYAs with cancer at an urban cancer centre and across Canada (n = 334). SNI was measured with the Berkman–Syme Social Network Index (SNI) and a modified version accounting for online interactions (SNI+). A multivariable logistic regression analysis was performed to identify factors associated with SNI and SNI+. A total of 54.8% and 68% of AYAs with cancer were classified as socially integrated with each measure, respectively. Living with others was associated with greater SNI and SNI+ (SNI OR = 3.27, 95% CI = 1.39, 7.72; SNI+ OR = 2.52, 95% CI = 1.14, 5.58), and an annual personal income of >CAD 80,000 was associated with greater SNI+ (SNI+ OR = 2.92, 95% CI = 1.09, 7.77). A significant proportion of AYAs with cancer are socially isolated. AYAs with cancer who live alone and whose personal income is less than CAD 80,000 are at a higher risk of social isolation. Digital technology could be leveraged to increase the SNI of AYAs with cancer.

Year:

2025

Year:

2025

A 9-year-old boy presented with edema of the left cheek. He was diagnosed with a large aneurysmal bone cyst of the mandibular bone. Off-label treatment with denosumab for 17 months resulted in a significant reduction in the lesion. Five months after discontinuing denosumab, the patient developed severe rebound hypercalcemia and acute kidney injury, which resolved with corticosteroids. Two years after treatment discontinuation, the lesion continues to decrease in size. This case highlights the efficacy of denosumab as an off-label treatment for aneurysmal bone cysts, though it can be associated with hypercalcemia and acute kidney injury. We conclude that the use of denosumab should be considered on a case-by-case basis, with regular monitoring for side effects.

Year:

2025

Background Patients with relapsed rhabdomyosarcoma (RMS) are treated with varying approaches and have a poor overall survival (OS). We performed an observational comparison of salvage regimens exploring whether high‐dose alkylator combinations were associated with longer OS. Procedure We categorized 110 patients with relapsed RMS from five institutions into two groups, those treated with regimens including a high‐dose alkylator (Group A) and those treated without a high‐dose alkylator (Group B). We compared OS between the two, adjusting for risk group at diagnosis and institution using Kaplan–Meier and Cox proportional hazards analyses. Results Median follow‐up in the 32 survivors was 4 years (range: 1.0–16.7 years) with a 28% (95% CI: 19%–37%) 4‐year OS. Group A patients had a longer OS compared to Group B (4‐year OS 41%, 95% CI: 27%–58%, vs. 14%, 95% CI: 4%–24%, respectively, p = 0.002). Adjustment for risk group at diagnosis abrogated the association (HR 1.4, 95% CI: 0.8–2.3, p = 0.16), while controlling for institution had no effect. In stratified analyses, patients with low risk at diagnosis had the highest effect size, suggesting a benefit after high‐dose alkylator regimens (stratified HR 4.4, 95% CI: 0.96–20.3, p = 0.06, reference Group A) compared to intermediate‐ (stratified HR 1.6, 95% CI: 0.9–3.2, p = 0.13) or high‐ (stratified HR 0.9, 95% CI: 0.4–1.8, p = 0.7) risk patients. Conclusions Patients with relapsed RMS and low‐risk group at diagnosis may benefit from high‐dose alkylator chemotherapy, while the high‐risk group has a dismal outcome regardless of treatment selection. It is inconclusive whether intermediate‐risk patients may benefit from such therapy.

Year:

2025

Adolescents and young adults (AYA) assigned female at birth with cancer face significant sexual health challenges, yet accessible, age-appropriate educational tools remain limited. This study evaluated a 13 min whiteboard video designed to improve sexual health knowledge. Female AYA patients aged 15–39 years across Canada completed pre- and post-video surveys assessing knowledge, attitudes, and satisfaction. The video’s understandability and actionability were measured using the Patient Education Materials Assessment Tool for Audiovisual Materials (PEMAT-A/V), and readability was assessed using six standard metrics. Quantitative analyses included paired t-tests and regression modeling; qualitative responses were thematically coded. Ninety participants completed the study. Knowledge scores increased by 19.5% (95% CI, 14–24%; p < 0.001, Cohen’s d = 0.89) following the video. Greater gains were observed among participants with a high school education or less (p = 0.040), while younger participants tended to show larger improvements. The video received average PEMAT-A/V scores of 96% for understandability and 94% for actionability. Most participants (89%) found it helpful for learning about sexual health and would recommend the video to peers, though suggested improvements included shorter length, enhanced visuals, and more age-specific content. Nearly half reported never discussing sexual health with providers. These findings support the feasibility of whiteboard video as an effective, scalable tool to address sexual health in oncology care.

Year:

2025

Year:

2025

Background Adolescents and young adults (AYA, 18–39) with high‐grade glioma (HGG) face unique challenges at a life stage focused on autonomy, careers, relationships, and family planning. Aim This study explores their experiences to inform life‐stage appropriate support and resources. Methods In this mixed‐methods study, we surveyed AYA HGG patients at Princess Margaret Cancer Centre (PM) to assess symptom experiences and care satisfaction. Interviews further explored their illness experiences and needs. Descriptive statistics summarized survey data, and thematic analysis guided by Braun and Clarke's framework identified key interview themes. Triangulation compared survey and interview results for a comprehensive understanding. Results Seventeen participants (7 men, 10 women; mean age 30.57) completed surveys and interviews. Triangulation revealed typical AYA challenges, such as delays in education, careers, and relationships, along with HGG‐specific issues. Three main themes emerged: (1) managing cognitive and treatment‐related impacts on life goals, (2) addressing physical and cognitive impairments affecting relationships, and (3) navigating identity loss and independence due to neurological symptoms. Conclusions These findings highlight the need for tailored interventions and educational support integrated into AYA HGG care pathways.

Year:

2025

Purpose: Non-inflamed (cold) tumors such as leiomyosarcoma do not benefit from immune checkpoint blockade (ICB) monotherapy. Combining ICB with angiogenesis or PARP inhibitors may increase tumor immunogenicity by altering the immune cell composition of the tumor microenvironment (TME). The DAPPER phase II study evaluated the safety, immunologic, and clinical activity of ICB-based combinations in pretreated patients with leiomyosarcoma. Patients and Methods: Patients were randomized to receive durvalumab 1,500 mg IV every 4 weeks with either olaparib 300 mg twice a day orally (Arm A) or cediranib 20 mg every day orally 5 days/week (Arm B) until unacceptable toxicity or disease progression. Paired tumor biopsies, serial radiologic assessments and stool collections were performed. Primary endpoints were safety and immune cell changes in the TME. Objective responses and survival were correlated with transcriptomic, radiomic, and microbiome parameters. Results: Among 30 heavily pretreated patients (15 on each arm), grade ≥ 3 toxicity occurred in 3 (20%) and 2 (13%) on Arms A and B, respectively. On Arm A, 1 patient achieved partial response (PR) with increase in CD8 T cells and macrophages in the TME during treatment, while 4 had stable disease (SD) ≥ 6 months. No patients on Arm B achieved PR or SD ≥ 6 months. Transcriptome analysis showed that baseline M1-macrophage and B-cell activity were associated with overall survival. Conclusions: Durvalumab plus olaparib increased immune cell infiltration of TME with clinical benefit in some patients with leiomyosarcoma. Baseline M1-macrophage and B-cell activity may identify patients with leiomyosarcoma with favorable outcomes on immunotherapy and should be further evaluated.

Year:

2025

Year:

2024

Year:

2023

Collaborators (17)

Sheila N. Garland

Professor

Memorial University

CANADA
View details

Aaron R. Hansen

Medical Oncologist

University Health Network

CANADA
View details

Benjamin Haibe-Kains

University of Toronto

CANADA
View details

Douglas Hawkins

Professor

University of Washington

UNITED STATES
View details

Albiruni R. Abdul Razak

University Health Network

CANADA
View details

Anna Spreafico

University Health Network

CANADA
View details

Sebastiano A.G. Lava

Chef de clinique

University College London

UNITED KINGDOM
View details

Marcus Butler

University Health Network

CANADA
View details

Lillian L. Siu

University Health Network

CANADA
View details

Bryan Coburn

University Health Network

CANADA
View details

Philippe L. Bedard

University Health Network

CANADA
View details

Jack Brzezinski

Associate Professor

University of Washington

UNITED STATES
View details

Eric William

Professor

Western University

CANADA
View details

Argerie Tsimicalis

Associate Professor

McGill University

CANADA
View details

Jacqueline Bender

Assistant Professor

University of Toronto

CANADA
View details

Fuchsia Howard

Associate Professor

The University of British Columbia

CANADA
View details

Nancy Baxter

Professor and Deputy Executive Dean

University of Sydney

AUSTRALIA
View details